COVID-19 in hematopoietic cell transplant recipients
Göster/ Aç
Erişim
info:eu-repo/semantics/openAccessTarih
2021Yazar
Altuntaş, FevziAta, Naim
Yigenoğlu, Tuğçe Nur
Başcı, Semih
Dal, Mehmet Sinan
Korkmaz, Serdal
Birinci, Şuayip
Turgut, Burhan
Üst veri
Tüm öğe kaydını gösterÖzet
In this study, we aim to report the outcome of COVID-19 in hematopoietic cell transplant (HCT) recipients. HCT recipients (n = 32) with hematological disease and hospitalized for COVID-19 were included in the study. A cohort of age and comorbid disease-matched hospitalized COVID-19 patients with hematological malignancy but not underwent HCT (n = 465), and another cohort of age and comorbid disease-matched hospitalized COVID-19 patients without cancer (n = 497) were also included in the study for comparison. Case fatality rate (CFR) was 5.6% in patients without cancer, 11.8 in patients with hematological malignancy and 15.6% in HCT recipients. The CFR in HCT recipients who were not receiving immunosuppressive agents at the time of COVID-19 diagnosis was 11.5%, whereas it was 33% in HCT recipients who were receiving an immunosuppressive agent at the time of COVID-19 diagnosis. In conclusion, our study reveals that for the current pandemic, HCT recipients, especially those receiving immunosuppressive drugs, constitute a special population of cancer patients.